Status report Elicera Therapeutics – Pushing the boundaries of immuno-oncology
Immuno-oncology has been changing cancer therapy during the last decade. On the front line of this development is Swedish Elicera Therapeutics – a clinical stage cell and gene therapy company developing immuno-oncology solutions through use of oncolytic viruses and CAR T-cells – two immunotherapies with the promising ability of boosting a patient’s immune system to help it fight cancer. The company’s iTANK technology platform takes these therapies to a whole new level by enhancing a patient’s immune system even further, giving rise to a multifaceted attack on tumours, something the competition is struggling to provide. BioStock has now published a status report of the company that can be downloaded below.
Elicera Therapeutics is set to be listed on Nasdaq First North Growth Market in June 2021, raising 52 MSEK in the process to advance its development programmes.
Download the status report below.
Disclaimer
This analysis is a Status Report by BioStock, conducted on commission by the analysed company. BioStock’s remuneration for the work has been agreed upon beforehand and is independent of the content and conclusions reached in the analysis. The content of this analysis is based solely on publicly available information gathered through research by the analyst from sources such as e.g. financial reports and statements, the company’s web page, public presentations and in dialogue with representatives of the company’s executive management. The information about the company was made available to the company for fact-checking and was published subsequent approval by the company. The analysis contains subjective assessments regarding future events and outcomes which should be considered to render such assessments to be uncertain. Any valuation of the company, products and/or markets has been made by BioStock’s analyst. The analyst does not own shares in the company. This analysis should not be considered as a recommendation or advice to invest in the company nor shall it be interpreted as financial advice of any sort. BioStock can not and does not give any guarantees that the conclusions or forecasts presented in this analysis will be fulfilled. BioStock can not be held responsible or liable for any damage, direct or indirect, caused by decisions made based on the information in this analysis. BioStock is not subject to the oversight of the Swedish financial authority Finansinspektionen and is thus not required to comply with the specific rules and guidelines that apply to analysis firms subject to the oversight of Finansinspektionen.
